Oric Pharmaceuticals Inc (ORIC)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $814.71M
Last updated: Nov 17, 2026 at 11:06 AM ET
Oric Pharmaceuticals Inc (ORIC) Competitors
The companies most similar to Oric Pharmaceuticals are Olema Pharmaceuticals (OLMA), Corvus Pharmaceuticals (CRVS) and Kura Oncology (KURA). By market cap, Oric Pharmaceuticals ranks 7th of the 13 companies on this page; Ocular Therapeutix (OCUL) is the largest at $1.37B.
Peer Comparison
ORIC's revenue growth of 0.0% is in line with the peer median. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Oric Pharmaceuticals (ORIC) | $814.71M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Olema Pharmaceuticals Inc (OLMA) | $662.30M | N/A | N/A | 0.0% | -53.8% | 0.0% | 0.00% |
| Corvus Pharmaceuticals Inc (CRVS) | $897.52M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Kura Oncology Inc (KURA) | $713.90M | N/A | 8.0x | 0.0% | -1125.3% | 10.1% | 0.00% |
| Rigel Pharmaceuticals Inc (RIGL) | $837.18M | 14.2x | 2.8x | 106.6% | 16.7% | 16.5% | 0.00% |
| Ovid Therapeutics Inc (OVID) | $479.38M | N/A | 335.8x | 0.0% | N/A | -88.3% | 0.00% |
| Omeros Corporation (OMER) | $1.27B | N/A | 16.4x | 324.9% | 33.6% | 14.9% | 0.00% |
| Inhibrx Biosciences, Inc. (INBX) | $1.23B | N/A | 610.4x | 0.0% | -66.0% | -100.0% | 0.00% |
| Immix Biopharma Inc (IMMX) | $657.09M | N/A | N/A | 0.0% | -14.9% | 0.0% | 0.00% |
| Theravance Biopharma Inc (TBPH) | $884.18M | 95.1x | 8.4x | 51.6% | N/A | -20.9% | 0.00% |
| Opus Genetics, Inc. (IRD) | $384.68M | N/A | 52.0x | 0.0% | -145.1% | -63.1% | 0.00% |
| Ocular Therapeutix Inc (OCUL) | $1.37B | N/A | 26.9x | 0.0% | -52.1% | -11.5% | 0.00% |
| Geron Corporation (GERN) | $622.98M | N/A | 2.9x | -22.0% | -7.4% | 27.4% | 0.00% |
| Peer median | $775.54M | 54.6x | 16.4x | 0.0% | -52.1% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Oric Pharmaceuticals, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Olema Pharmaceuticals Inc (OLMA) | Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development... | OLMA competitors |
| Corvus Pharmaceuticals Inc (CRVS) | Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. | CRVS competitors |
| Kura Oncology Inc (KURA) | Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops drugs for the treatment of cancer in the United States. | KURA competitors |
| Rigel Pharmaceuticals Inc (RIGL) | Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat blood disorders, cancer, and rare immune diseases. | RIGL competitors |
| Ovid Therapeutics Inc (OVID) | Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medications for patients and families with neurological disorders in the United States. | OVID competitors |
| Omeros Corporation (OMER) | Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and markets protein and small molecule therapies... | OMER competitors |
| Inhibrx Biosciences, Inc. (INBX) | Inhibrx, Inc., a clinical-stage biotechnology company, is focused on developing a line of new biological therapeutic candidates. | INBX competitors |
| Immix Biopharma Inc (IMMX) | Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, is dedicated to the development of various tissue-specific therapies in oncology... | IMMX competitors |
| Theravance Biopharma Inc (TBPH) | Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and markets organ-selective drugs in the United States, Europe... | |
| Opus Genetics, Inc. (IRD) | Opus Genetics, Inc. (IRD) is a pioneering biotechnology company dedicated to advancing gene therapies for rare retinal diseases that affect vision. | IRD competitors |
| Ocular Therapeutix Inc (OCUL) | Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development... | OCUL competitors |
| Geron Corporation (GERN) | Geron Corporation, an advanced stage clinical biopharmaceutical company, focuses on the development and commercialization of therapies for myeloid hematologic... | GERN competitors |
Frequently Asked Questions About ORIC
Who are Oric Pharmaceuticals' main competitors?
The companies most similar to Oric Pharmaceuticals include Olema Pharmaceuticals (OLMA), Corvus Pharmaceuticals (CRVS), Kura Oncology (KURA), Rigel Pharmaceuticals (RIGL) and Ovid Therapeutics (OVID), listed from the closest match.
Who is Oric Pharmaceuticals' biggest competitor?
Ocular Therapeutix (OCUL) is the largest of the similar companies at $1.37B; Olema Pharmaceuticals (OLMA) is the closest match by business profile, size, sector and industry.
How does ORIC stock compare with its competitors?
ORIC's net margin is 0.0% against a peer median of 0.0%.
Which of Oric Pharmaceuticals' competitors pays a higher dividend?
Oric Pharmaceuticals pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Oric Pharmaceuticals bigger than its competitors?
No. Oric Pharmaceuticals is 7th by market cap among the 13 companies on this page; the largest is Ocular Therapeutix (OCUL) at $1.37B.
ORIC pages: Overview, Earnings, Forecast, Financials, Competitors